RxDoctor Payments Data

Richard Grimsley, MD

Adult Reconstructive Orthopaedic Surgery · Jacksonville, FLNPI 1699779462

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (38.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Stryker at 38.2% of the total. Reporting peaked in 2020 at $7,833 and has fallen 80.4% since, to $1,533 in 2025.

$24,192in general payments, 2019–2025

Across 240 payments — averaging $100.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$9K
  • Techmah Medical, LLC$8K
  • Johnson & Johnson$1K
  • Encore Medical, LP$1K
  • Zimmer Biomet$860
  • Lima USA, Inc.$671
  • plus $3K from 31 others

What the payments were for

  • Consulting fees$6,12525%
  • Travel & lodging$9,41839%
  • Food & beverage$8,60436%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,192 in reported general payments places this provider in the 65th percentile of 96 adult reconstructive orthopaedic surgery providers in Florida.

See all adult reconstructive orthopaedic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$203,733
Medicare patients
328
Services billed
1,949

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$9,036
Celecoxib147$3,117
Oxycodone Hcl142$856
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen48$416
Meloxicam37$186
Ibuprofen17$129
Tramadol Hcl14$46
Cyclobenzaprine Hcl11$42
Amoxicillin31$24

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$662$9,03614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 96 adult reconstructive orthopaedic surgery providers in Florida.

Other adult reconstructive orthopaedic surgery in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →